Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
![Gilead Targets $3B in Oncology Revenue with 3 Key Drugs](https://pharmtales.com/wp-content/uploads/2023/08/Gileads-3B-Oncology-Milestone_-Trodelvy-Tecartus-and-Yescarta-Lead-the-Way-in-2023.jpg)
Gilead’s $3B Oncology Milestone: Trodelvy, Tecartus and Yescarta Lead the Way in 2023
Gilead Sciences has been making significant strides in the oncology space, fueled by the success of its rising star drug, ...
![Pfizer Meds in Short Supply After Tornado Hits Rocky Mount](https://pharmtales.com/wp-content/uploads/2023/08/Tornado-Wreaks-Havoc-on-Pfizers-Rocky-Mount-Plant-Causes-Drug-Shortages.jpg)
Tornado Wreaks Havoc on Pfizer’s Rocky Mount Plant, Causes Drug Shortages
Amid concerns of potential supply shortages of critical hospital drugs, Pfizer has taken precautionary measures in response to the tornado ...
![How Gilteritinib and Allo HSCT Can Boost Survival in AML](https://pharmtales.com/wp-content/uploads/2023/08/Gilteritinib-and-Allo-HSCT-Together-Increase-Survival-in-FLT3-Mutated-AML.jpg)
Gilteritinib and Allo HSCT Together Increase Survival in FLT3-Mutated AML
Results from a real-world study presented at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting indicate ...
![FDA Grants Orphan Status to ABM-1310 for Glioblastoma](https://pharmtales.com/wp-content/uploads/2023/08/ABM-1310-receives-Orphan-Drug-Designation-from-the-FDA-for-Glioblastoma.jpg)
ABM-1310 receives Orphan Drug Designation from the FDA for Glioblastoma
Source – ABM Therapeutics ABM Therapeutics has received orphan drug designation from the FDA for ABM-1310, a novel small molecule ...
![Meet Jeanne Marrazzo, the New NIAID Director After Fauci](https://pharmtales.com/wp-content/uploads/2023/08/Marrazzo-will-follow-Fauci-as-director-of-NIAID.jpg)
Marrazzo will follow Fauci as director of NIAID
After extensive deliberations, the National Institute of Allergy and Infectious Diseases (NIAID) has appointed a new director to succeed Dr. ...
![How PacBio’s Acquisition of Apton Biosystems Will Transform Sequencing](https://pharmtales.com/wp-content/uploads/2023/08/PacBio-to-Acquire-Apton-Biosystems-for-Next-Gen-Short-Read-Sequencer-Development.jpg)
PacBio to Acquire Apton Biosystems for Next-Gen Short-Read Sequencer Development
Source – PacBio Gene sequencing specialist PacBio has signed an agreement to acquire Apton Biosystems, a move that will enhance ...
![Bristol Myers and BeiGene’s Payment: A Twist After China’s Block](https://pharmtales.com/wp-content/uploads/2023/08/The-legacy-of-Bristol-Myers-and-BeiGene-Celgenes-payment-comes-years-after-Chinas-prohibition.jpg)
The legacy of Bristol Myers and BeiGene Celgene’s payment comes years after China’s prohibition
In 2020, an unexpected manufacturing issue led to a ban on the import of Bristol Myers Squibb’s (BMS) Abraxane, distributed ...
![COVID-19 Hits Merck KGaA’s CDMO Hard, CFO Shares Insights](https://pharmtales.com/wp-content/uploads/2023/08/Sharp-decline-in-COVID-related-sales-causes-CDMO-dip-at-Merck-KGaA-according-to-CFO.jpg)
CDMO Experiences Downturn at Merck KGaA as COVID-Related Sales Plunge, Says CFO
Merck KGaA is facing the challenges it anticipated for 2023, with its contract manufacturing division and process solutions arm experiencing ...
![Moderna Eyes Private COVID Market and RSV Launch as Sales Drop](https://pharmtales.com/wp-content/uploads/2023/08/Moderna-finds-promise-in-the-private-COVID-vaccination-market-and-the-debut-of-RSV-as-sales-plummet.jpg)
Moderna finds promise in the private COVID vaccination market and the debut of RSV as sales plummet
Source – Fiercepharma As Moderna continues its operations beyond the pandemic, the biotech firm has increased its revenue projection for ...
![A user of GLP-1 medications, a type of drugs that lower blood sugar and promote weight loss, has filed a lawsuit against Novo Nordisk and Eli Lilly. Read more about the case and its consequences.](https://pharmtales.com/wp-content/uploads/2023/08/A-user-of-well-known-GLP-1-medications-has-filed-a-lawsuit-against-Novo-Nordisk-and-Eli-Lilly-1.jpg)
A user of well-known GLP-1 medications has filed a lawsuit against Novo Nordisk and Eli Lilly
As Novo Nordisk and Eli Lilly enjoy significant sales from their GLP-1 diabetes and obesity drugs, they also face legal ...
![How Ervebo Can Protect Children Against Ebola Virus Disease](https://pharmtales.com/wp-content/uploads/2023/08/Mercks-Ervebo-has-received-US-FDA-approval-for-use-in-children-12-months-of-age-and-older.jpg)
Merck’s Ervebo has received US FDA approval for use in children 12 months of age and older
Source – Merck Merck announced that the US Food and Drug Administration (FDA) has granted expanded approval for Ervebo. The ...
![Urethral Cancer: A Rare but Serious Urological Condition](https://pharmtales.com/wp-content/uploads/2023/08/Urethral-Cancer_-A-Rare-but-Serious-Urological-Condition.jpg)
Understanding Urethral Cancer: Causes, Symptoms, Diagnosis, Treatment, And Prognosis
Introduction Of Urethral Cancer Urethral cancer is a rare type of cancer that affects the urethra, the tube that carries ...
![Karyopharm Cuts 20% of Staff as Xpovio Fails](https://pharmtales.com/wp-content/uploads/2023/08/Karyopharm-reduces-employees-by-20-as-Xpovio-sales-for-blood-cancer-remain-stagnant.jpg)
Karyopharm reduces employees by 20% as Xpovio sales for blood cancer remain stagnant
Source – Karyopharm Therapeutics Karyopharm Therapeutics, faced with stagnant sales of its only approved product, Xpovio (selinexor), has announced a ...
![Samsung Seeks Interchangeable Status for Humira Biosimilar](https://pharmtales.com/wp-content/uploads/2023/08/Samsung-wants-to-describe-its-Humira-biosimilar-as-_interchangeable.jpg)
Samsung wants to describe its Humira biosimilar as “interchangeable.”
While several biosimilars of AbbVie’s top-selling drug, Humira, are already available in the US market, only one, Boehringer Ingelheim’s Cyltezo, ...
![Teva’s Recovery Boosted by Austedo and Uzedy](https://pharmtales.com/wp-content/uploads/2023/08/With-Austedo-running-and-the-Uzedy-launch-underway-Teva-is-beginning-to-show-indications-of-improvement.jpg)
With Austedo running and the Uzedy launch underway, Teva is beginning to show indications of improvement
With a fresh growth strategy in place and two successful recent launches, Teva seems to be stepping into a new ...
![Teva’s $200M Deal to End Price-Fixing Probe](https://pharmtales.com/wp-content/uploads/2023/08/Teva-sets-aside-200-million-in-advanced-settlement-negotiations-to-end-the-US-price-fixing-investigation.jpg)
Teva sets aside $200 million in ‘advanced’ settlement negotiations to end the US price-fixing investigation
Teva, a pharmaceutical company facing a price-fixing indictment by the U.S. Department of Justice (DOJ), is taking steps to resolve ...
![GSK Sues Pfizer Over RSV Vaccine Patent](https://pharmtales.com/wp-content/uploads/2023/08/GSK-files-a-patent-infringement-lawsuit-against-Pfizer-as-the-RSV-vaccination-war-begins.jpg)
GSK files a patent infringement lawsuit against Pfizer as the RSV vaccination war begins
In the latest vaccine showdown, GSK and Pfizer are engaged in a legal battle over patent infringement claims. GSK alleges ...
![Biogen to sell biosims unit to Samsung Bioepis?](https://pharmtales.com/wp-content/uploads/2023/08/Is-Biogen-giving-up-its-biosims-business-to-Samsung-Bioepis.jpg)
Is Biogen giving up its biosims business to Samsung Bioepis?
During the first-quarter earnings call, CEO Chris Viehbacher discussed his plan to revitalize Biogen and emphasized the need to find ...
![AZ and BMS End Patent Disputes Over Checkpoint Inhibitors](https://pharmtales.com/wp-content/uploads/2023/08/Checkpoint-inhibitor-patent-challenges-are-settled-by-AZ-and-BMS.jpg)
Checkpoint inhibitor patent challenges are settled by AZ and BMS
AstraZeneca has announced the resolution of three lawsuits filed against it by Bristol-Myers Squibb (BMS) and Ono Pharma, alleging patent ...
![Jemperli Approved for First-Line Endometrial Cancer Therapy](https://pharmtales.com/wp-content/uploads/2023/08/Endometrial-Cancer-Patients-Get-New-Option-with-Jemperli.jpg)
Endometrial Cancer Patients Get New Option with Jemperli
Source – GSK GSK has secured approval from the US for Jemperli, in combination with chemotherapy, as a first-line treatment ...
![NICE Rejects CSL’s Hemophilia B Gene Therapy](https://pharmtales.com/wp-content/uploads/2023/08/Despite-CSLs-hemophilia-B-gene-therapy-NICE-is-not-persuaded.jpg)
Despite CSL’s hemophilia B gene therapy, NICE is not persuaded
The UK’s National Institute for Health and Care Excellence (NICE) has expressed hesitation in recommending approval for CSL Behring and ...
![Lonsurf Gets FDA Approval for Colorectal Cancer](https://pharmtales.com/wp-content/uploads/2023/08/Lonsurf-gets-a-boost-from-FDA-for-colorectal-cancer-challenging-rivals-Takeda-and-Hutchmed.jpg)
Lonsurf gets a boost from FDA for colorectal cancer, challenging rivals Takeda and Hutchmed
Source – Taiho Oncology Eight years after initially gaining FDA approval for the treatment of heavily pretreated colorectal cancer, Taiho ...
![IVS-3001 Gets Fast Track Status for RCC Treatment](https://pharmtales.com/wp-content/uploads/2023/08/IVS-3001-been-given-Fast-Track-Designation-by-the-FDA-for-RCC.jpg)
IVS-3001 been given Fast Track Designation by the FDA for RCC
The FDA has granted fast track designation (FTD) to IVS-3001, an innovative chimeric antigen receptor (CAR) T-cell therapy, intended for ...
![Boehringer’s Liposarcoma Drug Advances to Pivotal Trial](https://pharmtales.com/wp-content/uploads/2023/08/Boehringer-Launches-Pivotal-Trial-for-Liposarcoma-Drug.jpg)
Boehringer Launches Pivotal Trial for Liposarcoma Drug
Boehringer Ingelheim has initiated a registration trial for its investigational therapy, brigimadlin, as a potential treatment for dedifferentiated liposarcoma (DDLPS), ...
![Upifitamab Rilsodotin Fails in Ovarian Cancer Trial](https://pharmtales.com/wp-content/uploads/2023/08/Ovarian-Cancer_-Upifitamab-Rilsodotin-Misses-Primary-End-Point.jpg)
Ovarian Cancer: Upifitamab Rilsodotin Misses Primary End Point
Source – Mersana Therapeutics According to Mersana Therapeutics, the antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) did not achieve its ...
![EQRx Buys Revolution Medicines for $2.3B in Low-Cost Drugs Quest](https://pharmtales.com/wp-content/uploads/2023/08/How-EQRxs-Cheap-Drugs-Strategy-Led-to-Revolution-Deal.jpg)
How EQRx’s Cheap Drugs Strategy Led to Revolution Deal
Source – Revolution Medicines EQRx, which made a bold claim to disrupt the pharmaceutical pricing system in 2020, has now ...
![How Pfizer Plans to Survive the COVID Revenue Slump](https://pharmtales.com/wp-content/uploads/2023/08/As-COVID-revenues-fall-short-of-expectations-once-flying-Pfizer-considers-cost-cutting-measures.jpg)
As COVID revenues fall short of expectations, once-flying Pfizer considers cost-cutting measures
As the revenues from COVID-19 products fluctuate, mostly experiencing a decline, Pfizer is now considering implementing cost-cutting measures. During a ...
![New York Facility Closure Costs 161 Jobs at SterRx](https://pharmtales.com/wp-content/uploads/2023/08/Manufacturer-SterRx-closes-its-New-York-facility-and-fires-161-workers.jpg)
Manufacturer SterRx closes its New York facility and fires 161 workers
SterRx, a manufacturer based in New York, has closed its Plattsburgh plant and terminated 161 employees as a result. The ...
![How Jardiance Lifts Boehringer Ingelheim’s Revenue as US Decision Looms](https://pharmtales.com/wp-content/uploads/2023/08/Boehringer-Ingelheim-Soars-with-Jardiance-Growth-as-US-Kidney-Disease-Approval-Looms.jpg)
Boehringer Ingelheim Soars with Jardiance Growth as US Kidney Disease Approval Looms
Source – Boehringer Ingelheim Boehringer Ingelheim is gearing up for the launch of Jardiance, a diabetes and heart failure drug, ...